Biotech Behind Oxford’s Coronavirus Vaccine Welcomes AZ’s Big Pharma 'Muscle'
Vaccitech Hails Partner's ‘Aggressive’ Trial Design
Executive Summary
The University of Oxford spin-out is backing its academic partners to succeed against COVID-19 – but must also look to its own commercial future using the same adenovirus platform.
You may also be interested in...
Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020
Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.
Oxford’s Sarah Gilbert Outlines Coronavirus Vaccine Plans
Oxford University vaccines expert Sarah Gilbert says the first UK vaccine candidate to prevent the SARS-CoV-2 coronavirus will begin clinical testing in healthy volunteers next week and that “prospects are very good” an effective COVID19 jab could be available by September.
GSK Looks To Long-Acting Therapy To Restore Lead In HIV
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.